Skin Rash Vanishes When Cancer Drug Targets Inflammation in Rare Syndrome Case
A Swiss case report shows that the JAK1/2 inhibitor ruxolitinib completely resolved steroid-refractory histiocytoid Sweet syndrome in a polycythemia vera ...
A Swiss case report shows that the JAK1/2 inhibitor ruxolitinib completely resolved steroid-refractory histiocytoid Sweet syndrome in a polycythemia vera ...
The Danish DALIAH phase 3 trial found that low-dose pegylated interferon achieved superior long-term molecular responses to hydroxyurea in myeloproliferative ...
A systematic review and dose-response meta-analysis of 39 studies identifies 20 mg/kg/day as a population reference dose for hydroxyurea in ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine